Robert Terkeltaub

List of Publications by Citations

Source: https://exaly.com/author-pdf/176313/robert-terkeltaub-publications-by-citations.pdf
Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

158 papers	12,491 citations	62 h-index	110 g-index
189 ext. papers	14,091 ext. citations	6.8 avg, IF	6.38 L-index

#	Paper	IF	Citations
158	2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. *Arthritis Care and Research*, **2012**, 64, 1431-46	4.7	1061
157	Tissue-nonspecific alkaline phosphatase and plasma cell membrane glycoprotein-1 are central antagonistic regulators of bone mineralization. *Proceedings of the National Academy of Sciences of the United States of America*, **2002**, 99, 9445-9	11.5	657
156	2012 American College of Rheumatology guidelines for management of gout. Part 2: therapy and antiinflammatory prophylaxis of acute gouty arthritis. *Arthritis Care and Research*, **2012**, 64, 1447-61	4.7	507
155	Mutations in ENPP1 are associated with ‘idiopathic’infantile arterial calcification. *Nature Genetics*, **2003**, 34, 379-81	36.3	461
154	Concerted regulation of inorganic pyrophosphate and osteopontin by akp2, enpp1, and ank: an integrated model of the pathogenesis of mineralization disorders. *American Journal of Pathology*, **2004**, 164, 1199-209	5.8	388
153	Emerging regulators of the inflammatory process in osteoarthritis. *Nature Reviews Rheumatology*, **2015**, 11, 35-44	8.1	352
152	High versus low dosing of oral colchicine for early acute gout flare: Twenty-four-hour outcome of the first multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison colchicine study. *Arthritis and Rheumatism*, **2010**, 62, 1060-8		314
151	Innate immunity conferred by Toll-like receptors 2 and 4 and myeloid differentiation factor 88 expression is pivotal to monosodium urate monohydrate crystal-induced inflammation. *Arthritis and Rheumatism*, **2005**, 52, 2936-46		273
150	PC-1 nucleoside triphosphate pyrophosphohydrolase deficiency in idiopathic infantile arterial calcification. *American Journal of Pathology*, **2001**, 158, 543-54	5.8	250
149	Update on gout: new therapeutic strategies and options. *Nature Reviews Rheumatology*, **2010**, 6, 30-8	8.1	236
148	Generalized arterial calcification of infancy and pseudoxanthoma elasticum can be caused by mutations in either ENPP1 or ABCC6. *American Journal of Human Genetics*, **2012**, 90, 25-39	11	225
147	The interleukin 1 inhibitor rilonacept in treatment of chronic gouty arthritis: results of a placebo-controlled, monosequence crossover, non-randomised, single-blind pilot study. *Annals of the Rheumatic Diseases*, **2009**, 68, 1613-7	2.4	216
146	Colchicine update: 2008. *Seminars in Arthritis and Rheumatism*, **2009**, 38, 411-9	5.3	210
145	TLR2 signaling in chondrocytes drives calcium pyrophosphate dihydrate and monosodium urate crystal-induced nitric oxide generation. *Journal of Immunology*, **2005**, 174, 5016-23	5.3	189
144	Enzyme replacement therapy for murine hypophosphatasia. *Journal of Bone and Mineral Research*, **2008**, 23, 777-87	6.3	183
143	Monocyte-derived neutrophil chemotactic factor/interleukin-8 is a potential mediator of crystal-induced inflammation. *Arthritis and Rheumatism*, **1991**, 34, 894-903		160
142	Linked deficiencies in extracellular PP(i) and osteopontin mediate pathologic calcification associated with defective PC-1 and ANK expression. *Journal of Bone and Mineral Research*, **2003**, 18, 994-1004	6.3	159

141	Novel evidence-based colchicine dose-reduction algorithm to predict and prevent colchicine toxicity in the presence of cytochrome P450 3A4/P-glycoprotein inhibitors. *Arthritis and Rheumatism*, **2011**, 63, 2226-37		154
140	Inflammatory microcrystals stimulate interleukin-6 production and secretion by human monocytes and synoviocytes. *Arthritis and Rheumatism*, **1989**, 32, 1443-52		151
139	The inflammatory process of gout and its treatment. *Arthritis Research and Therapy*, **2006**, 8 Suppl 1, S3	5.7	149
138	IL-8/CXCL8 and growth-related oncogene alpha/CXCL1 induce chondrocyte hypertrophic differentiation. *Journal of Immunology*, **2003**, 171, 4406-15	5.3	148
137	Chondrogenesis mediated by PPi depletion promotes spontaneous aortic calcification in NPP1-/- mice. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2005**, 25, 686-91	9.4	148
136	Hypophosphatemia, hyperphosphaturia, and bisphosphonate treatment are associated with survival beyond infancy in generalized arterial calcification of infancy. *Circulation: Cardiovascular Genetics*, **2008**, 1, 133-40		144
135	Inflammation-induced chondrocyte hypertrophy is driven by receptor for advanced glycation end products. *Journal of Immunology*, **2005**, 175, 8296-302	5.3	144
134	Mitochondrial oxidative phosphorylation is a downstream regulator of nitric oxide effects on chondrocyte matrix synthesis and mineralization. *Arthritis and Rheumatism*, **2000**, 43, 1560-70		143
133	Cartilage cell clusters. *Arthritis and Rheumatism*, **2010**, 62, 2206-18		140
132	Ecto-phosphodiesterase/pyrophosphatase of lymphocytes and non-lymphoid cells: structure and function of the PC-1 family. *Immunological Reviews*, **1998**, 161, 11-26	11.3	135
131	Mitochondrial biogenesis is impaired in osteoarthritis chondrocytes but reversible via peroxisome proliferator-activated receptor coactivator 1. *Arthritis and Rheumatology*, **2015**, 67, 2141-53	9.5	127
130	Up-regulated expression of the phosphodiesterase nucleotide pyrophosphatase family member PC-1 is a marker and pathogenic factor for knee meniscal cartilage matrix calcification. *Arthritis and Rheumatism*, **2001**, 44, 1071-81		126
129	Genetics in arterial calcification: pieces of a puzzle and cogs in a wheel. *Circulation Research*, **2011**, 109, 578-92	15.7	124
128	Engagement of CD14 mediates the inflammatory potential of monosodium urate crystals. *Journal of Immunology*, **2006**, 177, 6370-8	5.3	120
127	The murine homolog of the interleukin-8 receptor CXCR-2 is essential for the occurrence of neutrophilic inflammation in the air pouch model of acute urate crystal-induced gouty synovitis. *Arthritis and Rheumatism*, **1998**, 41, 900-9		114
126	Chemokines and atherosclerosis. *Current Opinion in Lipidology*, **1998**, 9, 397-405	4.4	113
125	Low vitamin K status is associated with osteoarthritis in the hand and knee. *Arthritis and Rheumatism*, **2006**, 54, 1255-61		111
124	Differential mechanisms of inorganic pyrophosphate production by plasma cell membrane glycoprotein-1 and B10 in chondrocytes. *Arthritis and Rheumatism*, **1999**, 42, 1986-97		110

123	Interleukin-1 induces pro-mineralizing activity of cartilage tissue transglutaminase and factor XIIIa. *American Journal of Pathology*, **2001**, 159, 149-63	5.8	109
122	Matrix vesicle plasma cell membrane glycoprotein-1 regulates mineralization by murine osteoblastic MC3T3 cells. *Journal of Bone and Mineral Research*, **1999**, 14, 883-92	6.3	109
121	Chondrocyte AMP-activated protein kinase activity suppresses matrix degradation responses to proinflammatory cytokines interleukin-1 and tumor necrosis factor . *Arthritis and Rheumatism*, **2011**, 63, 1928-37		105
120	Extracellular signal-regulated kinase 1/extracellular signal-regulated kinase 2 mitogen-activated protein kinase signaling and activation of activator protein 1 and nuclear factor kappaB transcription factors play central roles in interleukin-8 expression stimulated by monosodium urate monohydrate crystals in human chondrocytes: implications for the inflammatory mechanism of crystal induced inflammation. *Arthritis and Rheumatism*, 2000, 43, 1445-55		103
119	Sustained osteomalacia of long bones despite major improvement in other hypophosphatasia-related mineral deficits in tissue nonspecific alkaline phosphatase/nucleotide pyrophosphatase phosphodiesterase 1 double-deficient mice. *American Journal of Pathology*, **2005**, 166, 1711-20	5.8	98
118	Recent developments in our understanding of the renal basis of hyperuricemia and the development of novel antihyperuricemic therapeutics. *Arthritis Research and Therapy*, **2006**, 8 Suppl 1, S4	5.7	95
117	A critical reappraisal of allopurinol dosing, safety, and efficacy for hyperuricemia in gout. *Current Rheumatology Reports*, **2009**, 11, 135-40	4.9	93
116	Invited review: the mitochondrion in osteoarthritis. *Mitochondrion*, **2002**, 1, 301-19	4.9	93
115	Lesinurad, a Selective Uric Acid Reabsorption Inhibitor, in Combination With Febuxostat in Patients With Tophaceous Gout: Findings of a Phase III Clinical Trial. *Arthritis and Rheumatology*, **2017**, 69, 1903-1913	9.5	92
114	Elevated skeletal osteopontin levels contribute to the hypophosphatasia phenotype in Akp2(-/-) mice. *Journal of Bone and Mineral Research*, **2006**, 21, 1377-86	6.3	92
113	Parathyroid hormone-related peptide is a naturally occurring, protein kinase A-dependent angiogenesis inhibitor. *Nature Medicine*, **2002**, 8, 995-1003	50.5	87
112	Chondrocyte innate immune myeloid differentiation factor 88-dependent signaling drives procatabolic effects of the endogenous Toll-like receptor 2/Toll-like receptor 4 ligands low molecular weight hyaluronan and high mobility group box chromosomal protein 1 in mice. *Arthritis and Rheumatism*, **2010**, 62, 2004-12		86
111	Mediation of spontaneous knee osteoarthritis by progressive chondrocyte ATP depletion in Hartley guinea pigs. *Arthritis and Rheumatism*, **2004**, 50, 1216-25		82
110	Rilonacept (interleukin-1 trap) for prevention of gout flares during initiation of uric acid-lowering therapy: results from a phase III randomized, double-blind, placebo-controlled, confirmatory efficacy study. *Arthritis Care and Research*, **2012**, 64, 1462-70	4.7	81
109	Physiologic and pathologic functions of the NPP nucleotide pyrophosphatase/phosphodiesterase family focusing on NPP1 in calcification. *Purinergic Signalling*, **2006**, 2, 371-7	3.8	81
108	The mutational spectrum of ENPP1 as arising after the analysis of 23 unrelated patients with generalized arterial calcification of infancy (GACI). *Human Mutation*, **2005**, 25, 98	4.7	80
107	Choline Uptake and Metabolism Modulate Macrophage IL-1 and IL-18 Production. *Cell Metabolism*, **2019**, 29, 1350-1362.e7	24.6	74
106	Causal link between nucleotide pyrophosphohydrolase overactivity and increased intracellular inorganic pyrophosphate generation demonstrated by transfection of cultured fibroblasts and osteoblasts with plasma cell membrane glycoprotein-1. Relevance to calcium pyrophosphate dihydrate deposition disease. *Arthritis and Rheumatism*, **1994**, 37, 934-41		74

105	Rilonacept (interleukin-1 trap) in the prevention of acute gout flares during initiation of urate-lowering therapy: results of a phase II randomized, double-blind, placebo-controlled trial. *Arthritis and Rheumatism*, **2012**, 64, 876-84		73
104	Lesinurad, a novel, oral compound for gout, acts to decrease serum uric acid through inhibition of urate transporters in the kidney. *Arthritis Research and Therapy*, **2016**, 18, 214	5.7	72
103	Increased hepatic levels of the insulin receptor inhibitor, PC-1/NPP1, induce insulin resistance and glucose intolerance. *Diabetes*, **2005**, 54, 367-72	0.9	71
102	AMP-activated protein kinase suppresses urate crystal-induced inflammation and transduces colchicine effects in macrophages. *Annals of the Rheumatic Diseases*, **2016**, 75, 286-94	2.4	67
101	Parathyroid hormone-related proteins is abundant in osteoarthritic cartilage, and the parathyroid hormone-related protein 1-173 isoform is selectively induced by transforming growth factor beta in articular chondrocytes and suppresses generation of extracellular inorganic pyrophosphate. *Arthritis and Rheumatism*, **1998**, 41, 2152-64		65
100	Proline-rich tyrosine kinase 2 and Src kinase signaling transduce monosodium urate crystal-induced nitric oxide production and matrix metalloproteinase 3 expression in chondrocytes. *Arthritis and Rheumatism*, **2004**, 50, 247-58		63
99	Plasma protein binding by monosodium urate crystals. Analysis by two-dimensional gel electrophoresis. *Arthritis and Rheumatism*, **1983**, 26, 775-83		63
98	New Perspectives in Rheumatology: Implications of the Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Morbidities Trial and the Associated Food and Drug Administration Public Safety Alert. *Arthritis and Rheumatology*, **2018**, 70, 1702-1709	9.5	62
97	Transamidation by transglutaminase 2 transforms S100A11 calgranulin into a procatabolic cytokine for chondrocytes. *Journal of Immunology*, **2008**, 180, 8378-85	5.3	61
96	Linked decreases in liver kinase B1 and AMP-activated protein kinase activity modulate matrix catabolic responses to biomechanical injury in chondrocytes. *Arthritis Research and Therapy*, **2013**, 15, R77	5.7	59
95	Gout. Novel therapies for treatment of gout and hyperuricemia. *Arthritis Research and Therapy*, **2009**, 11, 236	5.7	59
94	Role of interleukin-8 in PiT-1 expression and CXCR1-mediated inorganic phosphate uptake in chondrocytes. *Arthritis and Rheumatism*, **2005**, 52, 144-54		59
93	Evaluation of an instrument assessing influence of Gout on health-related quality of life. *Journal of Rheumatology*, **2008**, 35, 2406-14	4.1	58
92	Treatment of acute gout: a systematic review. *Seminars in Arthritis and Rheumatism*, **2014**, 44, 31-8	5.3	56
91	Peroxisome proliferator-activated receptor coactivator 1 and FoxO3A mediate chondroprotection by AMP-activated protein kinase. *Arthritis and Rheumatology*, **2014**, 66, 3073-82	9.5	56
90	Differential effects of aging on human chondrocyte responses to transforming growth factor beta: increased pyrophosphate production and decreased cell proliferation. *Arthritis and Rheumatism*, **1997**, 40, 1275-81		54
89	Serum uric acid is associated with carotid plaques: the National Heart, Lung, and Blood Institute Family Heart Study. *Journal of Rheumatology*, **2009**, 36, 378-84	4.1	53
88	Discordant American College of Physicians and international rheumatology guidelines for gout management: consensus statement of the Gout, Hyperuricemia and Crystal-Associated Disease Network (G-CAN). *Nature Reviews Rheumatology*, **2017**, 13, 561-568	8.1	52

87	One of two chondrocyte-expressed isoforms of cartilage intermediate-layer protein functions as an insulin-like growth factor 1 antagonist. *Arthritis and Rheumatism*, **2003**, 48, 1302-14		51
86	Differential effects of aging on human chondrocyte responses to transforming growth factor Increased pyrophosphate production and decreased cell proliferation. *Arthritis and Rheumatism*, **1997**, 40, 1275-1281		49
85	The pattern recognition receptor CD36 is a chondrocyte hypertrophy marker associated with suppression of catabolic responses and promotion of repair responses to inflammatory stimuli. *Journal of Immunology*, **2009**, 182, 5024-31	5.3	46
84	Gout, Hyperuricaemia and Crystal-Associated Disease Network (G-CAN) consensus statement regarding labels and definitions of disease states of gout. *Annals of the Rheumatic Diseases*, **2019**, 78, 1592-1600	2.4	45
83	C/EBP homologous protein drives pro-catabolic responses in chondrocytes. *Arthritis Research and Therapy*, **2013**, 15, R218	5.7	45
82	Role of the mevalonate pathway of isoprenoid synthesis in IL-8 generation by activated monocytic cells. *Journal of Leukocyte Biology*, **1994**, 55, 749-55	6.5	45
81	Subcellular targeting and function of osteoblast nucleotide pyrophosphatase phosphodiesterase 1. *American Journal of Physiology - Cell Physiology*, **2004**, 286, C1177-87	5.4	44
80	Inorganic pyrophosphate (PPI) in pathologic calcification of articular cartilage. *Frontiers in Bioscience - Landmark*, **2005**, 10, 988-97	2.8	44
79	Are either or both hyperuricemia and xanthine oxidase directly toxic to the vasculature? A critical appraisal. *Arthritis and Rheumatism*, **2012**, 64, 327-38		43
78	Transglutaminase 2 limits murine peritoneal acute gout-like inflammation by regulating macrophage clearance of apoptotic neutrophils. *Arthritis and Rheumatism*, **2006**, 54, 3363-71		43
77	Activation of AMPK-SIRT3 signaling is chondroprotective by preserving mitochondrial DNA integrity and function. *Osteoarthritis and Cartilage*, **2018**, 26, 1539-1550	6.2	42
76	Inorganic pyrophosphatase induces type I collagen in osteoblasts. *Bone*, **2010**, 46, 81-90	4.7	41
75	Gout, Hyperuricemia, and Crystal-Associated Disease Network Consensus Statement Regarding Labels and Definitions for Disease Elements in Gout. *Arthritis Care and Research*, **2019**, 71, 427-434	4.7	39
74	Lower prevalence of chondrocalcinosis in Chinese subjects in Beijing than in white subjects in the United States: the Beijing Osteoarthritis Study. *Arthritis and Rheumatism*, **2006**, 54, 3508-12		37
73	Development of Preliminary Remission Criteria for Gout Using Delphi and 1000Minds Consensus Exercises. *Arthritis Care and Research*, **2016**, 68, 667-72	4.7	37
72	What makes gouty inflammation so variable?. *BMC Medicine*, **2017**, 15, 158	11.4	36
71	Parallels between arterial and cartilage calcification: what understanding artery calcification can teach us about chondrocalcinosis. *Current Opinion in Rheumatology*, **2003**, 15, 302-10	5.3	33
70	Novel mouse model of autosomal semidominant adult hypophosphatasia has a splice site mutation in the tissue nonspecific alkaline phosphatase gene Akp2. *Journal of Bone and Mineral Research*, **2007**, 22, 1397-407	6.3	30

69	Npp1 promotes atherosclerosis in ApoE knockout mice. *Journal of Cellular and Molecular Medicine*, **2011**, 15, 2273-83	5.6	29
68	Racial disparities in the risk of Stevens-Johnson Syndrome and toxic epidermal necrolysis as urate-lowering drug adverse events in the United States. *Seminars in Arthritis and Rheumatism*, **2016**, 46, 253-258	5.3	29
67	Sex differences in gout characteristics: tailoring care for women and men. *BMC Musculoskeletal Disorders*, **2017**, 18, 108	2.8	28
66	Review: Unmet Needs and the Path Forward in Joint Disease Associated With Calcium Pyrophosphate Crystal Deposition. *Arthritis and Rheumatology*, **2018**, 70, 1182-1191	9.5	28
65	Vanin-1 pantetheinase drives smooth muscle cell activation in post-arterial injury neointimal hyperplasia. *PLoS ONE*, **2012**, 7, e39106	3.7	28
64	Serum urate is not associated with coronary artery calcification: the NHLBI Family Heart Study. *Journal of Rheumatology*, **2011**, 38, 111-7	4.1	27
63	Deficiencies of physiologic calcification inhibitors and low-grade inflammation in arterial calcification: lessons for cartilage calcification. *Joint Bone Spine*, **2005**, 72, 110-8	2.9	26
62	Gout Study Group: update on hyperuricemia and gout. *Joint Bone Spine*, **2009**, 76, 444-6	2.9	24
61	Exploration of metformin as novel therapy for osteoarthritis: preventing cartilage degeneration and reducing pain behavior. *Arthritis Research and Therapy*, **2020**, 22, 34	5.7	22
60	A delphi exercise to identify characteristic features of gout - opinions from patients and physicians, the first stage in developing new classification criteria. *Journal of Rheumatology*, **2013**, 40, 498-505	4.1	22
59	Dose-response relationship between lower serum magnesium level and higher prevalence of knee chondrocalcinosis. *Arthritis Research and Therapy*, **2017**, 19, 236	5.7	21
58	Review: Gout: A Roadmap to Approaches for Improving Global Outcomes. *Arthritis and Rheumatology*, **2017**, 69, 22-34	9.5	19
57	Calcium pyrophosphate dihydrate and hydroxyapatite crystal deposition in the joint: new developments relevant to the clinician. *Current Rheumatology Reports*, **2003**, 5, 235-43	4.9	19
56	RAGE signaling mediates post-injury arterial neointima formation by suppression of liver kinase B1 and AMPK activity. *Atherosclerosis*, **2012**, 222, 417-25	3.1	18
55	Calcium-containing crystals and osteoarthritis: implications for the clinician. *Current Rheumatology Reports*, **2005**, 7, 213-9	4.9	18
54	Low density lipoprotein inhibits the physical interaction of phlogistic crystals and inflammatory cells. *Arthritis and Rheumatism*, **1986**, 29, 363-70		17
53	Risk of gout flares after vaccination: a prospective case cross-over study. *Annals of the Rheumatic Diseases*, **2019**, 78, 1601-1604	2.4	14
52	Differential DNA Methylation of Networked Signaling, Transcriptional, Innate and Adaptive Immunity, and Osteoclastogenesis Genes and Pathways in Gout. *Arthritis and Rheumatology*, **2020**, 72, 802-814	9.5	13

51	Arhalofenate acid inhibits monosodium urate crystal-induced inflammatory responses through activation of AMP-activated protein kinase (AMPK) signaling. *Arthritis Research and Therapy*, **2018**, 20, 204	5.7	13
50	Modulation of matrix metabolism by ATP-citrate lyase in articular chondrocytes. *Journal of Biological Chemistry*, **2018**, 293, 12259-12270	5.4	13
49	Effect of Dietary and Supplemental Omega-3 Polyunsaturated Fatty Acids on Risk of Recurrent Gout Flares. *Arthritis and Rheumatology*, **2019**, 71, 1580-1586	9.5	12
48	Effect of Intensive Urate Lowering With Combined Verinurad and Febuxostat on Albuminuria in Patients With Type 2 Diabetes: A Randomized Trial. *American Journal of Kidney Diseases*, **2021**, 77, 481-489	7.4	12
47	inhibits ectopic joint calcification and maintains articular chondrocytes by repressing hedgehog signaling. *Development (Cambridge)*, **2018**, 145,	6.6	10
46	Efficacy and safety during extended treatment of lesinurad in combination with febuxostat in patients with tophaceous gout: CRYSTAL extension study. *Arthritis Research and Therapy*, **2019**, 21, 8	5.7	10
45	Impaired Proteasomal Function in Human Osteoarthritic Chondrocytes Can Contribute to Decreased Levels of SOX9 and Aggrecan. *Arthritis and Rheumatology*, **2018**, 70, 1030-1041	9.5	9
44	Integrated safety studies of the urate reabsorption inhibitor lesinurad in treatment of gout. *Rheumatology*, **2019**, 58, 61-69	3.9	9
43	Comparative tissue distribution of the processing enzymes "prohormone thiol protease," and prohormone convertases 1 and 2, in human PTHrP-producing cell lines and mammalian neuroendocrine tissues. *Endocrine*, **2001**, 15, 217-24		9
42	Mono-allelic and bi-allelic ENPP1 deficiency promote post-injury neointimal hyperplasia associated with increased C/EBP homologous protein expression. *Atherosclerosis*, **2014**, 233, 493-502	3.1	8
41	Prospective associations of C-reactive protein (CRP) levels and CRP genetic risk scores with risk of total knee and hip replacement for osteoarthritis in a diverse cohort. *Osteoarthritis and Cartilage*, **2018**, 26, 1038-1044	6.2	7
40	A Randomized, Phase II Study Evaluating the Efficacy and Safety of Anakinra in the Treatment of Gout Flares. *Arthritis and Rheumatology*, **2021**, 73, 1533-1542	9.5	7
39	Serum Metabolomics Identifies Dysregulated Pathways and Potential Metabolic Biomarkers for Hyperuricemia and Gout. *Arthritis and Rheumatology*, **2021**, 73, 1738-1748	9.5	7
38	Oral Treatment With an Engineered Uricase, ALLN-346, Reduces Hyperuricemia, and Uricosuria in Urate Oxidase-Deficient Mice. *Frontiers in Medicine*, **2020**, 7, 569215	4.9	5
37	Identifying potential classification criteria for calcium pyrophosphate deposition disease (CPPD): Item generation and item reduction. *Arthritis Care and Research*, **2021**,	4.7	5
36	Management of gout in chronic kidney disease: a G-CAN Consensus Statement on the research priorities. *Nature Reviews Rheumatology*, **2021**, 17, 633-641	8.1	5
35	A vascular smooth muscle cell X-box binding protein 1 and transglutaminase 2 regulatory circuit limits neointimal hyperplasia. *PLoS ONE*, **2019**, 14, e0212235	3.7	4
34	Pseudogout, hypomagnesemia, and liver transplantation. *Current Rheumatology Reports*, **2002**, 4, 243-4	4.9	4

33	Reference data based insights expand understanding of human metabolomes		4
32	The nomenclature of the basic disease elements of gout: A content analysis of contemporary medical journals. *Seminars in Arthritis and Rheumatism*, **2018**, 48, 456-461	5.3	3
31	Tophus Biology and Pathogenesis of Monosodium Urate Crystal-Induced Inflammation **2012**, 59-71		3
30	The effects of gamma-interferon on human peripheral blood monocyte/macrophage-mediated bone particle degradation. *Bone and Mineral*, **1990**, 8, 131-43		3
29	Reassessing the Cardiovascular Safety of Febuxostat: Implications of the Febuxostat versus Allopurinol Streamlined Trial. *Arthritis and Rheumatology*, **2021**, 73, 721-724	9.5	3
28	Thiazide diuretics and risk of knee replacement surgery among patients with knee osteoarthritis: a general population-based cohort study. *Osteoarthritis and Cartilage*, **2019**, 27, 1454-1461	6.2	2
27	Overview of Gout Therapy Strategy and Targets, and the Management of Refractory Disease **2012**, 194-208		2
26	The case for uricase in gout. *Current Rheumatology Reports*, **2003**, 5, 213-4	4.9	2
25	Diseases Associated with Articular Deposition of Calcium Pyrophosphate Dihydrate and Basic Calcium Phosphate Crystals **2009**, 1507-1524		2
24	Patients Prescribed Anakinra for Acute Gout Have Baseline Increased Burden of Hyperuricemia, Tophi, and Comorbidities, and Ultimate All-Cause Mortality. *Clinical Medicine Insights: Arthritis and Musculoskeletal Disorders*, **2019**, 12, 1179544119890853	2.3	2
23	Mitochondrial oxidative phosphorylation is a downstream regulator of nitric oxide effects on chondrocyte matrix synthesis and mineralization **2000**, 43, 1560		2
22	Monosodium urate crystals regulate a unique JNK-dependent macrophage metabolic and inflammatory response.. *Cell Reports*, **2022**, 38, 110489	10.6	2
21	Prophylaxis of Attacks of Acute Gouty Arthritis **2012**, 187-193		1
20	Are cherries now ripe for use as a complementary therapeutic in gout? Appraisal of the state of evidence. *Evidence-Based Medicine*, **2013**, 18, 230-1		1
19	The role of hypertension in cyclosporine-induced hyperuricemia. *Current Rheumatology Reports*, **2004**, 6, 215-6	4.9	1
18	Gout, Hyperuricaemia and Crystal-Associated Disease Network (G-CAN) common language definition of gout. *RMD Open*, **2021**, 7,	5.9	1
17	Parathyroid hormone-related protein is abundant in osteoarthritic cartilage, and the parathyroid hormone-related protein 1-173 isoform is selectively induced by transforming growth factor -in articular chondrocytes and suppresses generation of extracellular inorganic pyrophosphate **1998**, 41, 2152		1
16	Mitochondrial oxidative phosphorylation is a downstream regulator of nitric oxide effects on chondrocyte matrix synthesis and mineralization **2000**, 43, 1560		1

15	Colchicine prophylaxis is associated with fewer gout flares after COVID-19 vaccination.. *Annals of the Rheumatic Diseases*, **2022**,	2.4	1
14	Pathogenesis and Molecular Genetics of Calcium Pyrophosphate Dihydrate Crystal Deposition Disease **2012**, 240-248		0
13	Macrophage glucocorticoid receptors join the intercellular dialogue in atherosclerotic lesion calcification. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2008**, 28, 2096-8	9.4	0
12	Last call for alcohol in gout?. *Current Rheumatology Reports*, **2007**, 9, 229-30	4.9	0
11	Calcium Crystal Disease: Calcium Pyrophosphate Dihydrate and Basic Calcium Phosphate **2013**, 1576-1596.e4		0
10	Calcium Crystal Disease: Calcium Pyrophosphate Dihydrate and Basic Calcium Phosphate **2017**, 1645-1665.e4		
9	Reply. *Arthritis and Rheumatology*, **2019**, 71, 1967-1968	9.5	
8	Epilogue: Creating a Better Future of Diagnosis and Treatment of Gout and Other Crystal Arthropathies **2012**, 344-348		
7	A sugar transporter regulates serum urate levels: implications for prevention and management of hyperuricemia in gout. *Current Rheumatology Reports*, **2009**, 11, 83-6	4.9	
6	Hyperuricemia treatment: is creatinine clearance a safer allopurinol dosing meter than plasma creatinine levels?. *Nature Clinical Practice Rheumatology*, **2006**, 2, 68-9		
5	Inflammation de bas grade et d□ficit en inhibiteurs physiologiques de la calcification dans les calcifications des art□es: m□anismes permettant de comprendre les calcifications du cartilage. *Revue Du Rhumatisme (Edition Francaise)*, **2005**, 72, 186-194	0.1	
4	What do epidemiologic studies tell us about hyperuricemia and cardiovascular disease and death?. *Current Rheumatology Reports*, **2005**, 7, 211-2	4.9	
3	Molecular mechanisms of gouty arthritis: new insights into an old disease. *Pathology and Immunopathology Research*, **1984**, 3, 386-96		
2	Management of gout and hyperuricemia **2015**, 1575-1582		
1	Reply. *Arthritis and Rheumatology*, **2019**, 71, 481-482	9.5	